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ABSTRACT: We report the design and performance of a
polymer microfluidic device that can affinity select multiple
types of biological cells simultaneously with sufficient recovery
and purity to allow for the expression profiling of mRNA
isolated from these cells. The microfluidic device consisted of
four independent selection beds with curvilinear channels that
were 25 μm wide and 80 μm deep and were modified with
antibodies targeting antigens specifically expressed by two
different cell types. Bifurcated and Z-configured device
geometries were evaluated for cell selection. As an example
of the performance of these devices, CD4+ T-cells and neutrophils were selected from whole blood as these cells are known to
express genes found in stroke-related expression profiles that can be used for the diagnosis of this disease. CD4+ T-cells and
neutrophils were simultaneously isolated with purities >90% using affinity-based capture in cyclic olefin copolymer (COC)
devices with a processing time of ∼3 min. In addition, sufficient quantities of the cells could be recovered from a 50 μL whole
blood input to allow for reverse transcription-polymerase chain reaction (RT-PCR) following cell lysis. The expression of genes
from isolated T-cells and neutrophils, such as S100A9, TCRB, and FPR1, was evaluated using RT-PCR. The modification and
isolation procedures demonstrated here can also be used to analyze other cell types as well where multiple subsets must be
interrogated.
I solation of pure leukocyte subsets and their molecularanalysis from whole blood is challenged by the presence of
numerous interfering cells.1 The use of conventional isolation
methods such as density gradient centrifugation, sedimentation,
and fluorescence assisted cell sorting (FACS) is typically time-
consuming, requires large volumes of blood, and employs
sophisticated equipment. Microfluidics, however, are extremely
attractive for blood analysis because of the potentially short
assay turnaround times and the ability to design devices for
point-of-care applications.2,3
The use of microfluidics to isolate certain types of leukocytes
has attracted wide interest. For example, Cheng et al. reported a
two-stage microfluidic for the isolation of CD4+ T-cells; a
purity of ∼90% was achieved.4−6 Lee and co-workers
constructed a functionalized silicon and quartz nanowire array
to separate CD4+ T-cells from mouse splenocytes.7,8
Thorslund et al. fabricated a glass/PDMS/anti-CD4 micro-
fluidic chip containing different architectural features for CD4+
T-cell isolation.9 Warner et al. reported a microfluidic
neutrophil-capture device followed by gene expression analysis
to observe changes after trauma injury.10 They obtained purities
of 95% by processing 150 μL of whole blood through the chip
that isolated ∼25,000 cells and yielded 69 ng of RNA.
Common to these elegant examples was that only a single cell
type was isolated from the sample.
Stroke is the third leading cause of disability and death in the
United States.11 There are two types of stroke: (i) ischemic
stroke, caused by vessel occlusion, occurs at a frequency of 80−
85% and (ii) hemorrhagic stroke, resulting from vessel rupture,
is identified in 15−20% of all stroke-related cases. Unfortu-
nately, these two conditions cannot be differentiated using
existing clinical tests, which typically employ computed
tomography (CT) or magnetic resonance imaging (MRI).
Additionally, a third of all patients presenting stroke-like
symptoms actually suffer from nonvascular disease.12 It is
imperative that stroke diagnosis be made quickly and accurately
because treatments for ischemic and hemorrhagic stroke differ
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and there is a short time window (∼4.5 h) for effective
treatment.13−17
Because head-related trauma or stroke tissue is not easily
acquired and researchers have looked for markers in the
peripheral blood due to its accessibility,18−20 there have been
ongoing efforts to find reliable blood-based stroke biomarkers
that afford high clinical sensitivity and specificity.21 Several
potential biomarker candidates that can be measured in serum
or plasma have been identified with their role in the underlying
pathophysiology.22
Reports have shown that T-lymphocyte mediated anti-
inflammatory responses in ischemic brain injury23−26 and the
expression of nearly 5,700 genes related to T-cell function
change in cases of head trauma.27 mRNA can be harvested from
specific types of blood cells and used as biomarkers that reflect
the systemic changes in stroke.28 Transcripts of promise for
detecting and differentiating between ischemic and hemor-
rhagic stroke include S100A9 and IL1R2.29−32 Gene expression
studies conducted by Adamski et al. identified differential
expression across different leukocyte subsets, such as CD4+ T-
cells and neutrophils.33 These cells are known to express genes
found in stroke-related expression profiles.34 Therefore, the
ability to rapidly isolate these leukocyte subsets and secure their
mRNA expression profile without interference from other
leukocyte subsets could provide a viable test for diagnosing
various types of stroke.35−38 Isolation of pure fractions of these
subsets is critical to provide unbiased expression data.
In this manuscript, we report a microfluidic device that can
simultaneously isolate different types of cells using affinity
agents. As an example, we show the positive selection of CD4+
T-cells and CD66b+ neutrophils from minute amounts of
unprocessed blood. Total RNA (TRNA) was extracted from
the isolated cells and reverse transcribed to monitor mRNA
expression changes from the isolated cells. The selected subsets
were used to expression profile certain genes that possess
diagnostic value for stroke. The figures-of-merit for two device
geometries were evaluated as well as the applicability of two
different polymers, poly(methyl methacrylate), PMMA, and
cyclic olefin copolymer, COC, for optimizing antibody load and
cell recovery. We also introduce a chemical-based polymer
surface activation method that utilized sodium hydroxide and
isopropanol, which provided efficient and simple polymer
surface activation resulting in high antibody loads to improve
recovery.
■ EXPERIMENTAL SECTION
Materials and Reagents. PMMA (cover plates and
substrates), 6013S-04 COC cover plates, and 5013L-10 COC
substrates were purchased from Plaskolite (Columbus, OH)
and TOPAS Advanced Polymers (Florence, KY). Reagent-
grade isopropyl alcohol (IPA), 1-ethyl-3-[3-dimethylamino-
propyl] carbodimide hydrochloride (EDC), N-hydroxysuccini-
mide (NHS), 2-(4-morpholino)-ethane sulfonic acid (MES),
bovine serum albumin (BSA), Triton X-100, and paraformal-
dehyde (PFA) were obtained from Sigma-Aldrich (St. Louis,
MO). Phosphate buffered saline (PBS, pH = 7.4) was
purchased from Life Technologies (Grand Island, NY). Sodium
dodecyl sulfate (SDS), Micro-90, sodium hydroxide (NaOH),
and histological and laboratory grade IPA were received from
Fisher Scientific (Houston, TX), and toluidine blue O (TBO)
Figure 1. (A, D) Photograph of the four isolation beds filled with red dye in Z and bifurcated designs. (B, E) SEMs of the isolation beds for both the
bifurcated and Z devices. (C, F) Computational simulations showing the shear stresses in the inlet of the Z-configuration device and in the parallel
channels of the bifurcated device. (G) T-cells isolated from blood from the left in the 3, 2, 1, and 0 bifurcation levels of the bifurcated device. All
curvilinear channel dimensions are 25 × 80 μm (w × h), and the SEM scale bars are 1 mm for all micrographs.
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was from Carolina Biological Supply (Burlington, NC). Cy3-
l abe l ed o l i gonuc l eo t i de s (5 ′NH2 -C6 -TTT-TTT-
TTT-TTC-CGA-CAC-TTA-CGT-TTT-TTT-T-Cy3-3′) were
purchased from Integrated DNA Technology (Coralville, IA).
Low endotoxin antihuman CD4 antibodies (clone RPA-T4),
FITC-conjugated antihuman CD20 antibodies (clone AT80),
and PE-conjugated antihuman CD14 antibodies (clone TÜK4)
were purchased from AbD Serotec (Raleigh, NC). FITC-
conjugated anti-CD66b (clone CLB-B13.9) antibody was
obtained from Abcam (Cambridge, MA). Antihuman CD66b
antibodies (clone- G10F5) and 4′,6-diamidino-2-phenylindole
(DAPI) were obtained from BD Biosciences (San Jose, CA).
Microfluidic Device Fabrication and Assembly. In-
formation on device fabrication can be found in the Supporting
Information. The architectures for the 2 devices evaluated
herein differed in terms of addressing the selection beds (4 per
device), employing either a bifurcation network or Z-
configuration (Figures 1A,B,D,E and S1, Supporting Informa-
tion). In the Z-configuration device (Figure S1B, Supporting
Information), each cell isolation unit consisted of 64 curvilinear
channels that were 9,000 × 25 × 80 μm (l × w × h) with a
center-to-center spacing of 200 μm. Two 150 μm wide inlet
and outlet channels poised orthogonally to the isolation
channels addressed the selection bed. The surface area of a
single bed including inlet and outlet channel was 132.3 mm2
(1.9 mm2, 1.15 μL per channel).
The bifurcated device contained isolation beds with 16
curvilinear channels that were 11,000 × 25 × 80 μm (l × w ×
h) with a center-to-center spacing of 330 μm between channels
(Figure S1A, Supporting Information). Each isolation bed’s
surface area was 36.8 mm2 (2.3 mm2/channel) with a volume of
352 nL. Addressing each bed required four bifurcations with an
additional two bifurcations for the four independent isolation
units. All four isolation beds shared a common inlet port with
different outlet ports for each cell isolation unit (Figure 1D,E).
The total surface area, including the bifurcation network, was
43.4 mm2.
Chemical Surface Modification. Assembled devices were
filled with a mixture of 5:1 (v/v) 2 M NaOH/100% IPA using
input/output tubing sealed to the chip. Once filled, the chips
were incubated with the activating solution in a hybridization
oven (Boekel Scientific) for 12 h at 65 °C for COC and 30 min
at room temperature for PMMA unless otherwise noted. Chips
were rinsed with 1 mL of nanopure water.
Antibody (Ab) Immobilization to Activated Polymer
Surfaces. Ab immobilization was a two-step process. In the
first step, 50 mg/mL EDC and 5 mg/mL NHS in 100 mM
MES (pH = 4.8) was introduced into the device and incubated
for 15 min at room temperature followed by flushing with PBS.
Then, a 15 μL aliquot of 0.5 mg/mL mouse antihuman CD4 or
antihuman CD66b monoclonal antibody (mAb) was intro-
duced into the device and incubated overnight at 4 °C. The
selection bed was then rinsed with 1 mL of PBS (pH = 7.4).
Cell Isolation from Whole Blood and Staining. Whole
blood samples were obtained from anonymous healthy donors
at the UNC Blood Bank in accordance with UNC Institutional
Review Board (IRB) procedures. Peripheral blood samples
were collected by venipuncture in Vacutainer tubes containing
EDTA (7.5% in 0.06 mL; Tyco Health Care). Samples were
processed within 4 h following collection. Processing steps for
the blood samples using the microfluidic device are described in
the Supporting Information.
Flow Cytometric (FC) Analysis of Selected MOLT-3
Cells. MOLT-3 cells (human acute lymphoblastic leukemia)
were cultured as a suspension in 25 cm2 culture flasks (Cell
Treat Scientific, Shirley, MA) containing RPMI 1640 Medium
(Life Technologies, Grand Island, NY) supplemented with 10%
FBS (Life Technologies, Grand Island, NY). FC was performed
using a Beckman-Coulter CyAn instrument equipped with a 25
mW, 488 nm Coherent sapphire (blue) laser. Detailed
protocols for the FC analysis are presented in the Supporting
Information.
Evaluation of Carboxylic Acid Surface Densities. Cy3-
modified oligonucleotides containing a 5′ pendant amino group
served as fluorescent reporters by covalently labeling surface
confined carboxylic acids. Carboxylic acid surface densities were
also quantified by a colorimetric assay using TBO. Changes in
surface hydrophobicity were measured via water contact angle
measurements. Experimental details for these assays are
described in the Supporting Information.
Fluorescence Microscopy. Cell characterization was
performed by acquiring images on an Olympus IX71-DSU
Spinning Disk Confocal inverted microscope with DAPI, FITC,
and Texas Red filter sets, a mercury burner arc lamp, and high
sensitivity Hamamatsu EMCCD and high resolution Hama-
matsu ORCA-03G CCD cameras. Metamorph software was
used for analyzing and processing images. Exposure times for
DAPI, FITC, and Texas Red were 10, 300, and 500 ms,
respectively.
Reverse Transcription (RT) and Polymerase Chain
Reaction (PCR). CD4+ T-cells and neutrophils isolated on-
chip were lysed by infusing ∼20 μL of lysis solution (GenElute
Mammalian Total RNA Miniprep Kit, Sigma, St. Louis, MO)
through the cell selection bed. The effluent was collected into a
microfuge tube and purified using a total RNA miniprep kit
(Sigma) according to the manufacturer’s protocol with DNase
treatment (On-Column DNase I, Sigma, St. Louis, MO). After
purification of TRNA, reverse transcription (RT) was
accomplished using a ProtoScript II First Strand cDNA
Synthesis Kit (New England BioLabs, Ipswich, MA). Samples
were prepared by mixing 10 μL of reaction mix, 2 μL of poly-T
primer, 2 μL of enzyme (no enzyme, 2 μL of water for RT),
and 6 μL of TRNA. The samples were then incubated at 42 °C
for 1 h and heated to 80 °C for 5 min to deactivate the RT
enzyme. See Supporting Information for experimental details
on PCR.
Statistical Analysis and Computational Methods. Data
were analyzed using a student’s two-tailed t test (ANOVA).
Statistical significance was assigned where p < 0.0500. Shear
stress and flow uniformity through the bifurcated device was
evaluated using COMSOL Multiphysics 4.3b.39 Flow distribu-
tion analysis in the Z-configuration device employed a custom
numerical algorithm detailed elsewhere.40
■ RESULTS AND DISCUSSION
Polymer Surface Activation for Ab Attachment. Stable
attachment of mAbs to the surfaces of the selection bed, which
were made from a polymer, is critical for efficient recovery and
purity of the target cells. mAb surface density and uniformity
throughout the selection channel is dependent on the activation
protocol employed in cases where the mAb concentration
exceeds the surface functional group number (see Figure S2,
Supporting Information). We have reported that activating
microchannel surfaces via UV/ozone irradiation causes two
effects: (i) optical absorption by the bulk polymer with
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transmission decreasing with higher dose levels, which can
cause functional group surface densities to become increasingly
nonuniform as the aspect ratio of the channel is increased and
(ii) fragmentation of the polymer during irradiation reducing
functional group surface density, especially during thermal
fusion bonding. UV and thermally treated COC devices were
less susceptible to these artifacts compared to PMMA.39
We sought to avoid these effects by filling assembled devices
with an activating chemical solution. Therefore, we investigated
the use of a chemical modification protocol following thermal
assembly of the device. Microchannels were chemically
activated via incubation in 5:1 (v/v) 2 M NaOH/IPA solution.
In the case of PMMA, NaOH is known to hydrolyze PMMA’s
ester groups and we hypothesized that IPA encouraged
interaction with the hydrophobic polymer (water contact
angle of PMMA = 76.4 ± 1.4°, see Supporting Information)
and/or solvation of methoxide byproducts.41,42 Incubation of
PMMA with higher IPA/NaOH concentrations caused
irreversible channel deformation due to solvent swelling
(Figure S3C,D, Supporting Information).
Chemical activation of PMMA did not change the water
contact angle or carboxylic acid surface density as determined
by a TBO assay (see Supporting Information) relative to the
pristine surface; this was likely due to poor sensitivity of the
TBO assay in comparison to fluorescence assays using Cy3-
labeled oligonucleotides containing a pendant amino group that
served as a fluorescent reporter of surface-confined carboxylic
acids. Chemically activated PMMA microchannels derivatized
with Cy3-labeled oligonucleotides showed 232 ± 47 cps
compared to 503 ± 72 cps for UV-activated and thermally
treated PMMA microchannels (Figure S3A,E, Supporting
Information).
COC microchannels were subjected to a similar treatment
(5:1 (v/v) 2 M NaOH/IPA, see Supporting Information).
Chemical activation decreased COC’s water contact angle from
95.5 ± 1.8° (pristine) to 63.3 ± 3.2° and increased the carboxyl
surface density to 0.6 ± 0.2 nmol/cm2 as determined by the
TBO assay, which approached a theoretical monolayer (0.83
nmol/cm2). Carboxyl formation was also evident by
fluorescence analysis using Cy3-labeled oligonucleotide probes,
where the surface fluorescence intensity (4369 ± 437 cps) for
chemical modification was significantly greater than that
observed for the UV activated and thermally treated COC
microchannels (2357 ± 218 cps, see Figure S3B, Supporting
Information). The mechanism for carboxyl formation for COC
using these chemical conditions is currently unknown;
literature precedence necessitates a radical-forming catalyst,
such as Cu, Fe, or other heavy metals to convert alkanes, such
as those found in COC, directly to carboxylic acid groups.43 We
suspect that additives incorporated into the COC polymer
during manufacturing assist in forming the surface carboxylic
acids. On the basis of covalent labeling of surface-confined
carboxylic acids, chemical treatment of COC resulted in the
highest production of these surface functional groups.
Microfluidic Architectures and Performance Evalua-
tion. Two microfluidic devices were fabricated both of which
contained four separate isolation beds to facilitate the
simultaneous positive selection of multiple types of cells. We
chose to target T-cells using anti-CD4 and neutrophils using
anti-CD66b mAbs. In all cases, the concentration of mAb used
to optimize recovery was 0.5 mg/mL (see Figure S2,
Supporting Information). To facilitate simultaneous isolation
of T-cells within two beds and neutrophils in the remaining two
beds from a blood sample (Figure 1A,D), the beds were
modified by introducing the EDC/NHS solution through the
common inlet followed by mAb infusion through the individual
isolation bed outlets so that beds could be functionalized with
different mAbs. This design also enabled the lysis of each subset
contained within a bed for downstream analysis, such as mRNA
expression, by infusing a lysis solution through the common
inlet and lysate collection from the four separate outlets.
The two microfluidic devices differed in how the parallel
channels were addressed. In the first device (Figure 1D), a
bifurcation network was utilized to address 16 channels,
thereby requiring four bifurcations per isolation unit. The
second device (Figure 1A) employed a Z-configuration, where
inlet and outlet channels were poised orthogonal to the cell
selection channels (64 per device).39,40 Due to the larger
number of channels within the Z-configuration, this device had
a higher throughput; 50 μL of blood could be processed in 3
min maintaining a 2 mm/s linear velocity to optimize
recovery44 compared to 13 min for the bifurcated design.
Using a previously reported and experimentally validated
numerical algorithm,40 we calculated the flow distribution
through the Z-configuration and found that the linear velocity
ranged between 1.7 and 2.5 mm/s for each isolation bed in the
parallel arrangement (Figure S4B, Supporting Information).
For the bifurcated device (Figures S4A and S5, Supporting
Information), the fluid velocity within each isolation bed was
uniform. The variability in the flow velocity seen within each
isolation bed of the Z-configuration can result in variable cell
recoveries.
To evaluate the performance of the two microfluidic designs
and surface activation chemistry, T-cells and neutrophils were
isolated from blood and their recoveries determined. All cell
counts and purities are summarized in Table S1, Supporting
Information, and a box plot is shown in Figure 2A. In this
discussion, we differentiate the UV and chemical activation
modalities by UV- and CH-, respectively. For COC chips and
the bifurcated or Z-configuration, these were designated as UV-
COCbif and UV-COCZ, respectively, when UV activated and
CH-COCbif and CH-COCZ when chemically activated.
Initial testing of the bifurcated design indicated that, with
either activation protocol, COC outperformed PMMA devices.
UV-COCbif isolated 798 ± 167 CD4+ T-cells cells compared to
325 ± 85 cells for UV-PMMAbif from a 50 μL blood sample
input (Table S1, Supporting Information). These agree with
our previous results, which indicated efficient and uniform
activation in COC microchannels providing a higher mAb load
and, thus, higher recoveries for circulating tumor cells.39 CH-
PMMAbif devices demonstrated poor performance (7 ± 3
cells), which reflected the inability to chemically activate
PMMA without degrading microstructures (see Figure S3,
Supporting Information). Results for CH-COCbif devices (702
± 386 cells) showed no statistical difference (p = 0.631) to UV-
COCbif devices (798 ± 167) (Figure 2A). Chemical was as
efficient as UV activation for the bifurcated COC devices. Both
UV-COC devices produced nearly equally recovered T-cells for
the common input volume employed (50 μL): 798 ± 167 and
596 ± 154 using UV-COCbif and UV-COCZ devices,
respectively. Considering nearly the same cell recovery and
higher throughput, Z-configuration devices were used for the
remainder of these studies. While the bifurcation design could
be configured with a larger number of channels to increase
throughput, it comes at the expense of device footprint; the 64-
channel Z-configuration occupied an area of 35 × 45 mm2 (4
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selection beds) while the same number of channels for 4
selection beds using the bifurcation configuration would have
required an area of 128 × 160 mm2.
We observed higher cell recovery using CH-COCZ devices;
absolute cell counts increased from 596 ± 25 for UV-COCZ to
2565 ± 1194 for the CH-COCZ devices for T-cell isolation. In
the case of neutrophils, 1096 ± 537 cells were selected for the
UV-COCZ device compared to 2949 ± 901 for the CH-COCZ
device. However, we did not observe differences between the
activation modalities for bifurcated COC devices, which can be
explained by shear stress considerations.45 In bifurcated devices,
∼40% of cells was isolated in the bifurcation regions (Figure
1G), whereas only 4% was observed in the inlet and outlet
addressing channels of the Z-configuration. Inspection of the
bifurcation network showed that fluidic shear stress was
reduced from 11 dyn/cm2 in the parallel channels to 6−7
dyn/cm2 through the bifurcation network, where ∼17.7% of the
device’s surface area accounted for ∼40% of cell isolation.
Conversely, shear stress through the Z-configuration inlet and
outlet channels ranged between 1 and 38 dyn/cm2 along the
channel’s length and was <11 dyn/cm2 through the selection
channels.
For the Z-configuration, recovery occurred predominantly in
the cell isolation channels, where optical absorption of the
activating UV radiation may lead to reduced mAb loads;
activating polymer surfaces using chemical modification is not
sensitive to device aspect ratio. These effects may be precluded
in bifurcated devices due to cell isolation in the low aspect ratio
bifurcation regions (Figure 1F).
Recovery of Different Leukocyte Subsets. We observed
higher recoveries for CD4 T-cells (10.3 ± 0.5%) compared to
CD66b neutrophils (1.5 ± 0.1%) in the CH-COCZ devices,
assuming relative abundances of 25,000 and 200,000 cells/50
μL of blood for T-cells and neutrophils, respectively.46 This
difference in recovery may be related to the number of mAb
molecules immobilized to the surface. With the size of anti-
CD4 and anti-CD66b being 150 kDa IgG1 and 900 kDa IgM,
respectively, they will form monolayers where IgM is ∼36× less
abundant than a monolayer of IgG, possibly leading to lower
neutrophil recovery.39,47
Flow cytometric analysis was performed on T-cells and
neutrophils isolated from a buffy coat (as described in the
Supporting Information). For T-cells, CD4-FITC fluorescence
intensity was 5.3× greater than the IgG isotype control, and for
neutrophils, CD66b-FITC showed 4.6× greater intensity
compared to its IgM control. However, due to the surface
area of neutrophils (∼707 μm2) compared to smaller T-cells
(113 μm2), antigen density (C∞) of CD4 on T-cells is roughly
7× denser than CD66b on neutrophils. Consequently, the rate
of adhesion (kad) of T-cells to surface mAbs is ∼7× greater than
for neutrophils as stipulated by Chang and Hammer47
= ∞k k C Nad f r (1)
where (kf) is the effective antibody−antigen binding rate and
(Nr) is the antibody number. Thus, the ∼10-fold lower
recovery observed for neutrophils could be attributed to lower
surface density of the IgM anti-CD66b selection antibody and/
or reduced surface density of CD66b antigens on the
neutrophils. We also evaluated recovery of the MOLT-3 cell
line, which demonstrated a similar T-cell size but lower
expression of CD4 (Figure S6, Supporting Information). The
recovery of MOLT-3 cells was 0.5 ± 0.1% in the CH-COCZ
(see detailed discussion in Supporting Information).
We inspected the distribution of isolated cells throughout the
parallel channels of the Z-configuration device to relate cell
counts to linear velocity (Figure 2B). To discern the effects of
varying linear velocity on recovery, we normalized the
recovered cell counts to the total cell counts and plotted
these results as a function of linear velocity (Figure 2C). A
negative correlation between linear velocity and cell recovery
was observed for both T-cells (Pearson’s correlation, r = −0.65;
R2 = 0.42) and neutrophils (r = −0.72; R2 = 0.52). The
Figure 2. (A) Box plot comparing CD4+ T-cell recoveries from 50 μL
of healthy human blood in UV and chemically modified PMMA and
COC devices utilizing either bifurcated or Z-configuration. (∗)
indicates a statistically significant difference (student’s two tailed t
test p < 0.0500), while (∗∗) implies no statistically different results.
Solid lines in the boxes represent the median; the dotted line
represents the mean; the upper and lower edges of the boxes indicate
third and first quartiles, respectively; and error bars show maximum
and minimum values. (B) Distribution of T-cells and neutrophils in Z-
configuration parallel channels, which have varying linear velocities.
(C) Scatter plot of the data in (B) showing negative correlation
between the percentage of cells isolated in a parallel channel with the
linear velocity in that channel.
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magnitude of the slope suggested that neutrophils (m = −10.03
cells/mm/s) are more sensitive to linear velocity and fluidic
shear stress than T-cells (m = −5.17 cells/mm/s) due to the
effects of lower CD66b antigen surface density.
Purity of Isolated Leukocytes. When designing systems
for mRNA expression analysis of cell subsets isolated from
blood, it is critical to isolate pure fractions of the targets. For T-
cell isolation via CD4 positive selection, this is challenged by
the fact that CD4 is also expressed on the surface of monocytes,
macrophages, and dendritic cells at a frequency of 3−8% of the
total leukocyte population, but CD4 expression is lower
compared to T-cells (46,000−202,000 molecules/cell); thus,
their kad is lower as noted by eq 1.
4,48−50 This means that fluidic
shear stress can be used to potentially remove these low CD4
expressing cells due to low kad values.
Purity of isolated CD4+ T-lymphocytes was assessed by
immunostaining with CD66b, CD14, and CD20 Abs to identify
neutrophils (comprising 40−66% of total leukocyte popula-
tion), monocytes (4−8%), and B-cells (8−12%), respectively.3
Purity was defined as the ratio of DAPI+, CD14-, CD66b-, and
CD20-cells to the total number of nucleated cells. Fluorescence
images (Figure 3A−C) showed the absence of cells labeled with
CD14/66b/20 antibodies. Isolated cells showed intact
structures without an obvious change in morphology. It was
also observed that T-cells and neutrophils were distributed
randomly within the channel (outer and inner curvatures of the
curvilinear channels, Figure 1G) unlike circulating tumor cells,
which we have reported to be predominantly isolated along the
inner curvature.44 To confirm proper identification of T-cells,
an anti-CD3 marker was chosen because 87% of T-cells are
CD3+ and CD4+ (Figure 3D−F).51 For the UV-COCbif
devices, purities were 97 ± 1%, and CH-COCbif purities were
92 ± 5%, while the purity for the CH-COCZ for the CD4+ T-
cells was found to be 98 ± 1% (Table S1, Supporting
Information, and Figure 2A). The lack of contaminating cells
most likely resulted from their low CD4 expression and the
application of a shear stress between 6 and 11 dyn/
cm2.48,50,52,53
Lastly, we assessed neutrophil purity by counting double
positive DAPI and CD66b-FITC cells (Figure 3G−I). We
observed that some cells were DAPI+ and faint for CD66b-
FITC, but the dimensions and morphology of these cells were
consistent with neutrophils (Figure 3J−L).54 Neutrophil counts
isolated from 50 μL of blood using the UV-COCbif devices
averaged 918 ± 91 with a purity of 94 ± 3% and CH-COCZ
yielded purities of 97 ± 2% (see Table S1, Supporting
Information, for the raw data and Figure 2A for a box plot).
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR). The total number of isolated cells in the CH-
COCZ devices ranged from 500 to 3,500 CD4+ T-cells and
CD66b+ neutrophils. Considering an average of 10 pg of
TRNA per leukocyte, we expected to obtain 5−35 ng TRNA
(0.25 − 1.7 ng of mRNA) per bed, which should provide
sufficient material for cDNA synthesis and gene expression
analysis. To make sure that sufficient mRNA was harvested
from the T-cells and neutrophils for the expression analysis,
two beds were used for each cell type. T-cells and neutrophils
were isolated from the same blood sample using the CH-COCZ
chip, and because of the high purity of isolated fractions, cell
lysis was performed directly within each cell isolation bed.
Following lysis and TRNA extraction, an RT reaction was
performed. cDNA was then used for PCR with expression
analysis of 4 genes; S100A9, which has been shown to be
overexpressed following stroke38 and plays a prominent role in
the regulation of inflammatory processes and immune
response;55−57 TCRB and FPR1 genes, which are expressed at
various levels in T-cells and neutrophils;58−60 and GAPDH, a
housekeeping gene used as a reference. Figure 4A shows a
fluorescence image of the amplicons following gel electro-
phoresis. Although the expression of GAPDH can vary between
different types of cells,61 for these initial results, we normalized
the amplicon intensities to the intensity of the GAPDH
product.
As shown in Figure 4B for the T-cell population, we observed
significantly lower expression of S100A9 compared to the
neutrophil subset for this blood donor. T-cells showed a higher
expression of the TCRB gene compared to neutrophils;
however, some studies have demonstrated neutrophils that
express TCRB mRNA.62 FPR1 gene was expressed to a higher
level in neutrophils compared to T-cells, similar to that
reported in the literature.63 In the case of mRNA expression
profiling, if the purity of cell populations were not high, then
Figure 3. (A−F) Fluorescence microscopy images of CD4+ T-cells
isolated from whole blood using a bifurcated microfluidic device
immobilized with anti-CD4 Ab and stained with (A, D) DAPI (nuclear
stain); (B) CD20- and CD66b-FITC specific for B-lymphocytes and
neutrophils, respectively; (C) CD14-PE specific for monocytes; (E)
CD3-FITC specific for T-cells; and (F) no Ab used. Purity of CD4+ T
cells was defined as positive for DAPI and negative for PE and FITC
stains in (A−C), while specificity was demonstrated by dual staining of
cells with CD3-FITC and DAPI (D−F). Fluorescence microscopic
images of isolated neutrophils: (G) DAPI stained; (H) CD66b-FITC
stained; (I) no Ab used; and (J−L) a neutrophil that was (J) DAPI
stained with neutrophil morphology, (K) showed lack of CD66b-FITC
signal, and (L) no Ab used. Neutrophils were identified only if positive
for both DAPI and CD66b.
Analytical Chemistry Article
dx.doi.org/10.1021/ac5007766 | Anal. Chem. 2014, 86, 4058−40654063
the expression differences we noted in Figure 4B would not be
evident. For example, the differences in S100A9 expression
between neutrophils and T-cells would not have been observed
if either fraction was contaminated with other leukocyte types.
■ CONCLUSIONS
We have demonstrated an affinity-based microfluidic system
capable of isolating highly pure subsets of leukocytes from
whole blood. Processing 50 μL of whole blood within ∼3 min
provided sufficient genetic material for gene expression
profiling. Special emphasis was placed on the fluid dynamics
and design architecture of the device for T-cell and neutrophil
isolation to obtain high purity leukocytes fractions using a
single step. The isolation of two types of cells from whole blood
was accomplished with purity >90%.
We assessed the effects of polymer substrate and surface
activation modalities on cell recovery and discovered a chemical
activation method for COC, which can be useful for ultrahigh
aspect ratio microfluidic devices. High aspect ratio micro-
channels can be used to improve throughput reducing
processing time, which may be important for securing time-
sensitive diagnosis. For example, an FDA-approved therapeutic
treatment (tissue plasminogen activator) must be administered
within 3−4 h following onset of a stroke event.
The demonstrated results are not limited only to CD4+ T-
cells and CD66b+ neutrophils but can be expanded to analyze
other cell types simply by choosing different affinity agents for
the cells of interest. Furthermore, our microfluidic device
contains four individually addressable beds, permitting
simultaneous isolation of four individual cell subpopulations
from the same blood sample with sufficient material to perform
mRNA expression analysis on the isolated cells and can be
scaled to handle more subsets.
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